SaleMetabolic & GLP-1
Retatrutide
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
RETA-CA-26E-0199.637%
11.76 mg / 10 mg
$60.00$70.00CAD
- Form
- Lyophilized powder
Low on StockLongevity
BatchOVA-CA-26F-20
Ovagen Canada — 20 mg Lyophilized Vials, Janoshik-Tested
Peptide Bioregulator
Also known as Liver/ovary peptide bioregulator
Ovagen is a short synthetic peptide of the bioregulator class, studied in research within the framework of tissue-specific short-peptide regulators.
$100.00CAD
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
🔬 This product is coming soon — ordering is not yet available.
Purity VerifiedLab TestedSecure
Research Use Only
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Ovagen is a short synthetic peptide of the bioregulator class, studied in research within the framework of tissue-specific short-peptide regulators.
Experimental framing draws on the broader peptide-bioregulator literature, as direct studies are limited.
Purity
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 20mg lot is being finalised and will be published here as soon as the lab returns it.
Compound Properties
Overview
Ovagen belongs to the family of short peptide bioregulators investigated for proposed tissue-specific regulatory activity. Direct published research on Ovagen specifically is minimal; the compound is framed within the broader short-peptide-bioregulator research field, including work on gene-expression and protein-synthesis regulation by short peptides.
Research context is provided by class-level studies rather than compound-specific trials.
History
Ovagen arises from research programs into short regulatory peptides proposed to act on specific tissues.
Compound-specific literature is effectively absent; context derives from the short-peptide-bioregulator field.
Key Research Areas
Direct research on Ovagen is minimal. Context is drawn from the short-peptide-bioregulator literature on gene-expression and protein-synthesis regulation. Reference support is thin and class-level rather than compound-specific.
3 of the 3 areas below are addressed directly by a paper cited on this page.
Short-peptide bioregulator class models
Addressed on this page by Umnov 2013, Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Umnov, RS. et al. (2013) — [Neuroprotective effects of peptides bioregulators in people of various age]
- Khavinson, V. et al. (2020) — EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
Gene-expression regulation by short peptides
Addressed on this page by Khavinson 2020, Umnov 2013. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, V. et al. (2020) — EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
- Umnov, RS. et al. (2013) — [Neuroprotective effects of peptides bioregulators in people of various age]
Tissue-specific peptide research frameworks
Addressed on this page by Khavinson 2020, Umnov 2013. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, V. et al. (2020) — EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
- Umnov, RS. et al. (2013) — [Neuroprotective effects of peptides bioregulators in people of various age]
The references section of this page cites 2 primary papers published between 2013 and 2020 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Ovagen is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Ovagen, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Preclinical only
Ovagen is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under short-peptide bioregulator class models, gene-expression regulation by short peptides and tissue-specific peptide research frameworks.
The 2 papers cited on this page, published between 2013 and 2020 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Not supported
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. Ovagen rests on 2 cited papers (between 2013 and 2020). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Ovagen is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Ovagen in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Solvent selection depends on the compound; consult the published literature
- Format
- Lyophilized powder
Ovagen is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Included
- 1 × sealed glass vial in the strength selected (20mg / Single Vial, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- Canada Post Xpresspost, tracked, typically 1–2 business days from Canadian stock
Not included
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of ovagen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
Researchers also order
Sale
SaleMetabolic & GLP-1
Tirzepatide
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$35.00$40.00CAD
Metabolic & GLP-1
Semaglutide
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$70.00CAD
Metabolic & GLP-1
Eloralintide (LY3841136)
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$150.00CAD